Michael
Analyst
Morgan Stanley
Equibles does not estimate personal net worth.
About Michael
Michael is recorded as Analyst at Morgan Stanley. Michael has spoken on 3 earnings calls and 5 other investor events across 8 companies, most recently for Arrowhead Pharmaceuticals, Inc. on September 15, 2026. Those appearances were for Arrowhead Pharmaceuticals, Inc. (ARWR), Rocket Pharmaceuticals, Inc. (RCKT), Alnylam Pharmaceuticals, Inc. (ALNY), Sarepta Therapeutics, Inc. (SRPT), Rhythm Pharmaceuticals, Inc. (RYTM) and 3 other companies. The companies whose calls Michael spoke on are classified in the Healthcare and Technology sectors.
Michael on recent calls
“Hello, everyone, and thanks for joining us at the Morgan Stanley Global Health Care Conference. I'm Michael. It's one of the biotech analysts here, and it's my pleasure to introduce the team from Arrowhead Pharmaceuticals.”
“Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Health Care Conference. I'm Michael. It's one of the biotech analysts here. It's my pleasure to introduce Gaurav Shah, CEO of Rocket Pharmaceuticals.”
“Hello, everyone, and thanks for joining us at the Morgan Stanley Global Health Care Conference. I'm Michael. It's one of the biotech analysts here. It's my pleasure to introduce the team from El Nilem Pharmaceuticals.”
“All right, good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael, one of the biotech analysts here, and it's my pleasure to introduce the team from Sarepta Therapeutics.”
“Maybe just a follow-up on the HO launch, just in terms of the greater than 150 start forms. Maybe if you can compare that to your internal expectations at the beginning of the launch.”
Affiliation history
-
Morgan Stanley
Analyst
Transcript header (unverified)
Current
Company network
Clearwater Analytics Holdings, Inc.
Software - Application · Technology
Recent activity
-
-
-
-
-
-
-
-
Earnings call
Clearwater Analytics Holdings, Inc. Q4 FY2023 Earnings Call
Clearwater Analytics Holdings, Inc.